This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Watanabe, M. Articles by Tsuruo, T. Search for Related Content PubMed PubMed Citation Articles by Watanabe, M. Articles by Tsuruo, T.

Cellular Pharmacology of MX2, a New Morpholino Anthracycline, in Human Pleiotropic Drug-resistant Cells¹

Pharmaceutical Research Laboratory, Kirin Brewery Co., Ltd., Miyahara-machi, Takasaki, Gunma 370-12 [M. W., N. K.]; Institute of Applied Microbiology, University of Tokyo, Yayoi, Bunkyo-ku, Tokyo 113 [M. N., T. I., T. T.]; and School of Science and Engineering, Teikyo University, Nagaoka-cho, Utsunomiya, Tochigi 320 [N. O.], Japan

We previously reported that MX2, a new morpholino anthracycline, showed marked effects on pleiotropic drug-resistant sublines of murine P388 leukemia in vivo as well as in vitro. In this study we examine the in vitro cytotoxicity against pleiotropic drug-resistant sublines of human tumor cell lines. MX2 was effective against multidrug-resistant sublines of four human tumor cell lines; these cells, having a 4.8- to 200-fold cross-resistance to Adriamycin (ADM) showed only a 0.7- to 2.3-fold resistance to MX2 compared with the sensitive cells.

To elucidate the mechanism by which MX2 overcomes multidrug resistance, the intracellular pharmacology of MX2 in human myelogenous leukemia K562 and its ADM-resistant subline (K562/ADM) was examined. Both K562 and K562/ADM cells accumulated MX2 more easily than ADM, and the intracellular accumulation of MX2 attained a steady state in both cell lines within 30 min of incubation at 37°C. The amount of MX2 that accumulated in K562/ADM at a steady state was only 1.3 times lower than that in K562. However, ADM was accumulated slowly in both cell lines compared with MX2, and the intercellular concentration reached a steady state in K562/ADM after 90 min of incubation and in K562 after more than 120 min. K562/ADM cells accumulated a 3.3-fold lower concentration of ADM than K562 after 120 min of exposure. The steady-state concentration of ADM in K562/ADM was 8.3 times lower than that of MX2. In addition, >70% of MX2 was retained in both cell lines after 150 min of incubation in the absence of this drug. Verapamil, a calcium antagonist, hardly augmented the cytotoxicity of MX2 against K562/ADM, and no distinct effect of this drug on both the time course and the maximal level of accumulation of MX2 was observed. Interestingly, MX2 effectively inhibited ATP/Mg²⁺-dependent [³H]vincristine binding to K562/ADM membrane preparations, indicating that MX2 could be transported outside the cell by an active efflux pump. The high intracellular accumulation and retention of MX2 in K562/ADM through the rapid influx of the drug into the cells may be one of the reasons why MX2 circumvents pleiotropic drug resistance.

¹ Supported by a Grant-in-Aid for Cancer Research from the Ministry of Education, Science, and Culture, Japan.

² To whom requests for reprints should be addressed.

Received 11/ 6/90. Accepted 4/10/90.

This article has been cited by other articles:

				K. Clarke, R. L. Basser, C. Underhill, P. Mitchell, J. Bartlett, L. Cher, M. Findlay, D. Dalley, M. Pell, M. Byrne, et al. KRN8602 (MX2-Hydrochloride): An Active New Agent for the Treatment of Recurrent High-Grade Glioma J. Clin. Oncol., August 1, 1999; 17(8): 2579 - 2579. [Abstract] [Full Text] [PDF]